Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,504.00
Bid: 12,504.00
Ask: 12,506.00
Change: 106.00 (0.85%)
Spread: 2.00 (0.016%)
Open: 12,432.00
High: 12,506.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

A quarter of symptomatic kids hit by long COVID; mRNA shots provide best protection in breast milk

Mon, 14th Mar 2022 18:42

March 14 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

One in four kids with COVID develop lingering problems

One in four children with COVID-19 symptoms develop "long COVID," according to data pooled from 21 earlier studies conducted in Europe, Asia, Australia and South America.

Among the 80,071 children with COVID-19 in the studies, 25% developed symptoms that lasted at least 4-to-12 weeks or new persistent symptoms that appeared within 12 weeks, researchers reported on Sunday on medRxiv https://www.medrxiv.org/content/10.1101/2022.03.10.22272237v1 ahead of peer review. The most frequent problems were neuropsychiatric (mood symptoms, fatigue, sleep disorders, headaches, cognitive alterations, dizziness, balance problems), cardiorespiratory (breathing difficulty, congestion, exercise intolerance, chest pain and tightness, cough, irregular heart rhythm), skin-related (excessive sweating, itchiness, hair loss) and gastrointestinal (abdominal pain, constipation, diarrhea, vomiting, and nausea). Analyses of data pooled from many different studies with different methodologies cannot yield firm conclusions, the researchers acknowledge. What is clear, however, is that "children and adolescents have also physical and mental health consequences derived from COVID-19," said study coauthor Sonia Villapol of Houston Methodist Research Institute in Texas.

"Identifying the main signs and symptoms of pediatric long COVID can help diagnose, develop better treatments, create multidisciplinary teams for optimal clinical management, and find risk factors for prevention."

Vaccine protection in mother's milk strongest after mRNA shots

Women who wish to pass protective antibodies induced by COVID-19 vaccines to their babies via breast milk should opt for the mRNA shots from Moderna or Pfizer/BioNTech , according to a study reported on Monday in JAMA Pediatrics https://jamanetwork.com/journals/jamapediatrics/fullarticle/2789947.

For the study, 124 lactating women each provided 17 milk samples over a period of 100 days. The women had received either an mRNA vaccine or a vector-based vaccine from Johnson & Johnson or AstraZeneca. Researchers measured two types of antibodies in the milk samples - IgA antibodies and IgG antibodies, both of which are thought to play important roles in protecting breastfed infants. Nearly all - 96% to 97% - of the women who received both doses of an mRNA vaccine had detectable IgA antibodies in their milk, while only 39% had antibodies in their milk after two doses of the AstraZeneca shot and 48% after the one-dose J&J vaccine. All the women who received both doses of the Pfizer/BioNTech, Moderna or AstraZeneca vaccines had IgG antibodies, compared to only 28% of women who received J&J's shot.

"An mRNA-based COVID-19 vaccine is the optimal choice for lactating women when they want to transfer breast milk antibodies to their infants," the researchers concluded.

Omicron is infectious on surfaces longer than original virus

Omicron particles remain infectious on surfaces for longer periods than particles of the original SARS-CoV-2, according to laboratory experiments.

Researchers put droplets of infectious virus from the original coronavirus version and the Omicron BA.1 variant on a variety of surfaces at room temperature. On smooth surfaces (glass, stainless steel and plastic sheet), Omicron was still infectious after seven days, whereas particles of the original SARS-CoV-2 were no longer infectious on stainless steel and plastic sheets by day 4 and on glass by day 7, the researchers reported on Thursday on bioRxiv https://www.biorxiv.org/content/10.1101/2022.03.09.483703v1 ahead of peer review. On tissue paper and printing paper, the original virus was no longer infectious at 30 minutes. Omicron was still infectious at 30 minutes, but no longer after an hour, the researchers said.

For the most part, SARS-CoV-2 is transmitted via respiratory droplets in the air. While infection via contact with contaminated surfaces is less common, the new study "highlights the importance of hand hygiene and cleaning on surfaces that are regularly touched by different persons," said study coauthor Leo Poon of the University of Hong Kong. "For surfaces and settings contaminated by a COVID-19 patient, proper cleaning should be done."

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

More News
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.